Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 16/20 | 0.57 |
| ▸ | KDR | P35968 | 16/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.57 |
| ▸ | KIT | P10721 | 10/20 | 0.52 |
| ▸ | CSF1R | P07333 | 2/20 | 0.52 |
| ▸ | FLT4 | P35916 | 2/20 | 0.52 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | HLA-A | P04439 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | FRK | P42685 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.52 |
| ▸ | STK3 | Q13188 | 1/20 | 0.52 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.52 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.52 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.52 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090589 | 1.00 | FLT1 (0.57) | FLT1KDRPDGFRBKITCSF1R | |
| Aniline SCHEMBL27606669 | 0.94 | FLT1 (0.59) | FLT1KDRPDGFRBKITCSF1R | |
| Bromobenzene SCHEMBL27606664 | 0.91 | FLT1 (0.53) | FLT1KDRPDGFRBKITCSF1R | |
| Chlorobenzene SCHEMBL27534363 | 0.91 | FLT1 (0.59) | FLT1KDRPDGFRBKITCSF1R | |
| Trifluoromethylbenzene SCHEMBL27625245 | 0.89 | KDR (0.54) | FLT1KDRPDGFRBKITCSF1R | |
| Anisole SCHEMBL27606840 | 0.87 | KDR (0.58) | FLT1KDRPDGFRBKITSHMT2 | |
| SCHEMBL27625233 | 0.83 | KDR (0.59) | FLT1KDRPDGFRBKITCSF1R | |
| Succinic Acid SCHEMBL27967574 | 0.83 | FLT1 (0.66) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL24997217 | 0.79 | FLT1 (0.72) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL7663797 | 0.79 | FLT1 (0.59) | FLT1KDRPDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE (US) | 2025-06-17 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220110954-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220110954-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, PKM, PDK2 | FLT1 405/4885KDR 380/4885PDGFRB 765/4885 |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | PDK1, PKM, PDK2 | FLT1 405/4885KDR 380/4885PDGFRB 765/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | FLT1 2193/4885KDR 1277/4885PDGFRB 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.